Compare DOMO & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DOMO | MSLE |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | Canada |
| Employees | N/A | 17 |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.6M | 146.9M |
| IPO Year | 2018 | N/A |
| Metric | DOMO | MSLE |
|---|---|---|
| Price | $3.76 | $7.73 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $10.28 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 52.0K |
| Earning Date | 05-20-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $318,857,000.00 | N/A |
| Revenue This Year | $3.41 | N/A |
| Revenue Next Year | $4.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $2.39 | $5.50 |
| 52 Week High | $18.49 | $13.39 |
| Indicator | DOMO | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 54.01 | 51.69 |
| Support Level | $2.39 | $6.73 |
| Resistance Level | $4.11 | $8.37 |
| Average True Range (ATR) | 0.31 | 0.75 |
| MACD | 0.06 | 0.14 |
| Stochastic Oscillator | 75.76 | 33.83 |
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.